摘要
宫颈癌是世界范围内第二大常见妇科肿瘤,每年有>230 000人死于宫颈癌。导致宫颈癌的危险因素主要为持续性高危型人乳头状瘤病毒感染宫颈的移行带上皮,其机制可能是机械性原因,也可能是生物性原因。通过免疫干预可以打破免疫耐受,重新激发机体免疫系统消除肿瘤细胞的能力,随着免疫学和基因工程学的发展,免疫治疗已成为临床肿瘤治疗的第4种治疗模式。本文对近年来宫颈癌的HPV相关筛查和免疫治疗进展进行综述。
Cervical cancer is the second most common gynecologic tumor in the world,the person excess of 230 000 die of cervical cancer every year. The risk factors leading to cervical carcinoma is persistent high-risk human papilloma virus infection of cervical epithelium transitional belt, its mechanism may be mechanical or biological reasons. By immune intervention it can break the immune tolerance, to stimulate the body＇s immune system to eliminate the ability of tumor cells,with the development of immunology and genetic engineering,clinical tumor immunotherapy has be- come a fourth treatment modes of treatment. In this paper the content related to HPV screening for cervical cancer and immunotherapy progress were summarized in recent years.
出处
《中国现代医生》
2013年第28期19-21,共3页
China Modern Doctor
关键词
HPV
宫颈癌
免疫治疗
HPV
Cervical cancer
Immunotherapy
